Collectively, our findings suggest that the NASP/ANXA2/STAT3 axis is a potential therapeutic target for improving the prognosis of patients with GBM, which has important implications for the development of more effective and precise cancer treatments. The gene discussed is ANXA2; the disease is cancer.